How much funding has NK-One Therapeutics raised?

NK-One Therapeutics has disclosed $290K raised across 1 round.

Where is NK-One Therapeutics headquartered?

NK-One Therapeutics is headquartered in Wayne, US.

NK-One Therapeutics

Wayne, US · Founded 2026 · Delaware corporation

NK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.

Biotech Healthtech

Founders & leadership

Marco PappagalloSecretary

Michael ShineChief Executive Officer and President

MikeCEO

Dr. PappagalloChief Medical Officer / Medical Advisor

PaulDrug Development Lead

Reported raises · per SEC filings

Form D private placements

$290K disclosed across 1 round · 2026

▶$290KraisedApr 2026 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Marco PappagalloExecutive Officer, Director
Michael ShineExecutive Officer, Director

Offering amount: $310K
Amount sold: $290K
First sale: Mar 2026
Incorporated: Corporation, Delaware, 2026
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap

NKore Biotherapeutics9 shared keywordsNKore BioTherapeutics is a cellular-based biotherapeutics company developing an allogeneic immunotherapy platform based on a proprietary method of activating natural killer (NK) cells, called Supercharged NK (sNK) cells. Its lead therapy, NK101, targets solid and blood cancers in adult and pediatric patients, with human clinical trials planned in the United States beginning in 2027.

Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Nkarta, Inc.8 shared keywordsNkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.

Companies competing with NK-One Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does NK-One Therapeutics do?: NK-One Therapeutics is a biotechnology company developing a first-in-class intrathecal molecular therapy (SP-SAP) that selectively disables NK-1 receptor pain-signaling neurons in the spine to treat refractory pain in end-stage cancer patients. The therapy is in a Phase 1 clinical trial and is also intended for veterinary use.
How much funding has NK-One Therapeutics raised?: NK-One Therapeutics has disclosed $290K raised across 1 round.
Where is NK-One Therapeutics headquartered?: NK-One Therapeutics is headquartered in Wayne, US.